Compare TCMD & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TCMD | FLGT |
|---|---|---|
| Founded | 1995 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 548.2M | 511.0M |
| IPO Year | 2016 | 2016 |
| Metric | TCMD | FLGT |
|---|---|---|
| Price | $22.56 | $22.14 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $36.00 | $28.33 |
| AVG Volume (30 Days) | 240.5K | ★ 282.1K |
| Earning Date | 05-04-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 17.14 | N/A |
| EPS | ★ 0.26 | N/A |
| Revenue | N/A | ★ $18,730,000.00 |
| Revenue This Year | $11.60 | $10.09 |
| Revenue Next Year | $9.14 | $12.18 |
| P/E Ratio | $88.04 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.48 | $13.46 |
| 52 Week High | $37.77 | $31.04 |
| Indicator | TCMD | FLGT |
|---|---|---|
| Relative Strength Index (RSI) | 45.05 | 67.85 |
| Support Level | $21.29 | $19.12 |
| Resistance Level | $27.67 | $23.83 |
| Average True Range (ATR) | 0.66 | 0.64 |
| MACD | 0.23 | 0.09 |
| Stochastic Oscillator | 74.23 | 98.92 |
Tactile Systems Technology Inc is a medical technology company. The company is engaged in developing and providing medical devices for the treatment of chronic diseases. The firm's proprietary platform flexitouch system, provides a home-based solution for lymphedema patients. The entire system is another home solution for patients with chronic swelling and actitouch system for chronic venous insufficiency patients that may be worn throughout the day.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.